Other Notable Approvals
First drug approval for sickle cell disease in nearly 20 years. Indicated to reduce severe complications of sickle cell disease in adults and children aged 5 years or older.
First approved therapy specifically for adults with eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome.
First PCSK9 inhibitor approved to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.